Ad
related to: traveler's diarrhea and cipro
Search results
Results From The WOW.Com Content Network
Travelers' diarrhea (TD) is a stomach and intestinal infection. TD is defined as the passage of unformed stool (one or more by some definitions, three or more by others) while traveling. [ 2 ] [ 3 ] It may be accompanied by abdominal cramps, nausea, fever, headache and bloating. [ 3 ]
If your diarrhea lasts longer than a couple of days, Dr. Ahmad suggests calling your doctor, especially if you also have a fever, dehydration, bloody stool, weight loss, pain, and severe pain.
Unfortunately, resistance toward ciprofloxacin in Enteroaggregative E.coli (EAEC) strains has been reported in several studies. [15] For most people treatments include rest and the intake of fluids. Patients with profuse diarrhea or vomit should be rehydrated by drinking much water or by drinking rehydration solutions such as Rehydralyte or ...
Enterotoxigenic Escherichia coli (ETEC) is a type of Escherichia coli and one of the leading bacterial causes of diarrhea in the developing world, [1] as well as the most common cause of travelers' diarrhea. [2] Insufficient data exists, but conservative estimates suggest that each year, about 157,000 deaths occur, mostly in children, from ETEC.
Rifaximin, sold under the brand name Xifaxan among others, is a non-absorbable, broad-spectrum antibiotic mainly used to treat travelers' diarrhea. It is based on the rifamycin antibiotics family. Since its approval in Italy in 1987, it has been licensed in more than 30 countries for the treatment of a variety of gastrointestinal diseases like ...
Ciprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. [5] This includes bone and joint infections , intra-abdominal infections, certain types of infectious diarrhea , respiratory tract infections , skin infections, typhoid fever , and urinary tract infections , among others. [ 5 ]
In 1983 a $10 million six story biosciences building was constructed on the grounds. In the 1990s NAMRU-3 pioneered studies into prophylaxis of traveler's diarrhea with norfloxacin and treatment with ciprofloxacin and lopramide. In 1998, NAMRU-3 became part of the newly reorganized Naval Medical Research Center. [2] [3]
Areas of research included malaria, vaccines and travelers’ diarrhea. [7] [8] [9] He conducted a study on the oral antibiotic formulation Rifamycin SV – MMX for treating traveler’s diarrhea and also promoted researches on the interests of older travelers. [10] [11] Lately he focused on a viral infection called Tick-borne encephalitis (TBE ...